Cargando…

The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

IMPORTANCE: A number of officially approved disease-modifying drugs (DMD) are currently available for the early intervention in patients with relapsing-remitting multiple sclerosis (RRMS). The aim of the present study was to systematically evaluate the effect of DMDs on disability progression in RRM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsivgoulis, Georgios, Katsanos, Aristeidis H., Grigoriadis, Nikolaos, Hadjigeorgiou, Georgios M., Heliopoulos, Ioannis, Papathanasopoulos, Panagiotis, Kilidireas, Constantinos, Voumvourakis, Konstantinos, Dardiotis, Efthimios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671570/ https://www.ncbi.nlm.nih.gov/pubmed/26642051 http://dx.doi.org/10.1371/journal.pone.0144538

Ejemplares similares

The Effect of Disease Modifying Therapies on Brain Atrophy in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis
por: Tsivgoulis, Georgios, et al.
Publicado: (2015)

The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials
por: Tsivgoulis, Georgios, et al.
Publicado: (2016)

Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece
por: Dardiotis, Efthymios, et al.
Publicado: (2022)

“Liberation treatment” for chronic cerebrospinal venous insufficiency in multiple sclerosis: the truth will set you free
por: Tsivgoulis, Georgios, et al.
Publicado: (2015)

Cytokines as Biomarkers of Treatment Response to IFNβ in Relapsing-Remitting Multiple Sclerosis
por: Dimisianos, Nikolaos, et al.
Publicado: (2014)

Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options
por: Andravizou, Athina, et al.
Publicado: (2019)

Multiple Sclerosis: Shall We Target CD33?
por: Siokas, Vasileios, et al.
Publicado: (2020)

Impact of Body Mass Index on the Age of Relapsing-Remitting Multiple Sclerosis Onset: A Retrospective Study
por: Siokas, Vasileios, et al.
Publicado: (2021)

Remitting–relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab
por: Mouzaki, Athanasia, et al.
Publicado: (2010)

Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens
por: Rodi, Maria, et al.
Publicado: (2016)

Repetitive Transcranial Magnetic Stimulation, Cognition, and Multiple Sclerosis: An Overview
por: Nasios, Grigorios, et al.
Publicado: (2018)

Immune responses against Helicobacter pylori-specific antigens differentiate relapsing remitting from secondary progressive multiple sclerosis
por: Efthymiou, Georgios, et al.
Publicado: (2017)

Long-Term Effectiveness of Natalizumab in Patients with Relapsing-Remitting Multiple Sclerosis Treated in the Routine Care in Greece: Results from the Multicenter, Observational 5-Year Prospective Study ‘TOPICS Greece’
por: Efthimios, Dardiotis, et al.
Publicado: (2021)

Efficacy of a Computer-Assisted Cognitive Rehabilitation Intervention in Relapsing-Remitting Multiple Sclerosis Patients: A Multicenter Randomized Controlled Trial
por: Messinis, Lambros, et al.
Publicado: (2017)

Virus-mediated autoimmunity in Multiple Sclerosis
por: Grigoriadis, Nikolaos, et al.
Publicado: (2006)

Deciphering the role of DNA methylation in multiple sclerosis: emerging issues
por: Sokratous, Maria, et al.
Publicado: (2016)

Cognitive and Language Deficits in Multiple Sclerosis: Comparison of Relapsing Remitting and Secondary Progressive Subtypes
por: Ntoskou, Katerina, et al.
Publicado: (2018)

Phase III, randomised, double-blind, placebo-controlled trial of Neuroaspis plp10 as an adjuvant treatment for relapsing multiple sclerosis: the MINERAL Study
por: Pantzaris, Marios C, et al.
Publicado: (2022)

Cognitive Impairment in Relapsing Remitting and Secondary Progressive Multiple Sclerosis Patients: Efficacy of a Computerized Cognitive Screening Battery
por: Papathanasiou, Athanasios, et al.
Publicado: (2014)

Important advances in stroke research in 2020
por: Tsivgoulis, Georgios, et al.
Publicado: (2021)

Gene variants of adhesion molecules act as modifiers of disease severity in MS
por: Dardiotis, Efthimios, et al.
Publicado: (2017)

Moyamoya Disease May Mimic Multiple Sclerosis?
por: Spanou, Ioanna, et al.
Publicado: (2019)

The Role of TOR1A Polymorphisms in Dystonia: A Systematic Review and Meta-Analysis
por: Siokas, Vasileios, et al.
Publicado: (2017)

Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease
por: Vakrakou, Aigli G., et al.
Publicado: (2023)

Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease
por: Marogianni, Chrysoula, et al.
Publicado: (2020)

Anti-MOG Positive Bilateral Optic Neuritis and Brainstem Encephalitis Secondary to COVID-19 Infection: A Case Report
por: Tsouris, Zisis, et al.
Publicado: (2022)

Cognitive trajectories preluding the imminent onset of Alzheimer’s disease dementia in individuals with normal cognition: results from the HELIAD cohort
por: Liampas, Ioannis, et al.
Publicado: (2022)

Language Differences Among Individuals with Normal Cognition, Amnestic and Non-Amnestic MCI, and Alzheimer’s Disease
por: Liampas, Ioannis, et al.
Publicado: (2022)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Observational Study Assessing Demographic, Economic and Clinical Factors Associated with Access and Utilization of Health Care Services of Patients with Multiple Sclerosis under Treatment with Interferon Beta-1b (EXTAVIA)
por: Hadjigeorgiou, Georgios, et al.
Publicado: (2014)

Reperfusion Therapies of Acute Ischemic Stroke: Potentials and Failures
por: Tsivgoulis, Georgios, et al.
Publicado: (2014)

Association of Ultrasonographic Parameters with Subclinical White-Matter Hyperintensities in Hypertensive Patients
por: Heliopoulos, Ioannis, et al.
Publicado: (2012)

Gene variants of adhesion molecules predispose to MS: A case-control study
por: Dardiotis, Efthimios, et al.
Publicado: (2019)

Real-world comparative safety and efficacy of tenecteplase versus alteplase in acute ischemic stroke patients with large vessel occlusion
por: Psychogios, Klearchos, et al.
Publicado: (2021)

Relapsing Remitting Multiple Sclerosis in X-Linked Charcot-Marie-Tooth Disease with Central Nervous System Involvement
por: Koutsis, Georgios, et al.
Publicado: (2015)

Phonological Fluency Strategy of Switching Differentiates Relapsing-Remitting and Secondary Progressive Multiple Sclerosis Patients
por: Messinis, L., et al.
Publicado: (2013)

Sexual dysfunction therapeutic approaches in patients with multiple sclerosis: a systematic review
por: Giannopapas, Vasileios, et al.
Publicado: (2022)

Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center
por: Boziki, Marina, et al.
Publicado: (2021)

Correction: Observational study assessing demographic, economic and clinical factors associated with access and utilization of health care services of patients with multiple sclerosis under treatment with interferon beta-1b (EXTAVIA)
por: Hadjigeorgiou, Georgios, et al.
Publicado: (2015)

Potential Role of Antibodies against Aquaporin-1 in Patients with Central Nervous System Demyelination
por: Pechlivanidou, Maria, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fjgaclh37rgl8o4ov0ghcrira7